Floatz logo

Bavituximab

Hepatocellular Carcinoma

University of Texas Southwestern Medical Centermonoclonal_antibodyPhase 2Active
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
65/ 100

Competitive context

520 Active assets in the Hepatocellular Carcinoma cohort.

Asset / SponsorPhaseRating
Adefovir
Bukwang Pharmaceutical
Phase 4BBB
Huaier Granule
Tongji Hospital
Phase 4BBB
Sorafenib
Bayer
Phase 4BBB
Carboplatin
AstraZeneca
Phase 4BB
Theprubicin
RWTH Aachen University
Phase 4BB

View all 50 →

Same molecule, other indications

Bavituximab is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
64 / 100
View asset →
Non-Small Cell Lung CancerDormant
CCC
Indicative ·
54 / 100
View asset →
triple-negative breast carcinomaDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →